{"entity":{"id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","aka":[],"tldr":"A phase 1/2 trial of TQB6411 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","summary":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection is a phase 1/2 interventional study registered as NCT07367529 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 465 participants planned, started 2026-02-26 and due to reach its primary completion in 2028-12. Interventions recorded: TQB6411 for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07367529","url":"https://clinicaltrials.gov/study/NCT07367529"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb6411"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07367529","phase":"1/2","setting":"A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","enrolled":465,"outcomes":[]},"route":"/trials/nct07367529/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}